Changes in serum basic fibroblast growth factor concentration following intracordal injection

Area of Science:

• Regenerative Medicine
• Otolaryngology
• Biochemistry

Background:

• Intracordal trafermin injections are used to improve voice outcomes.
• Limited data exists on serum basic fibroblast growth factor (bFGF) changes post-injection.
• Understanding bFGF dynamics is crucial for assessing safety and efficacy.

Purpose of the Study:

• To investigate changes in serum bFGF concentrations following intracordal trafermin injection.
• To determine if there is a correlation between trafermin dosage and serum bFGF levels.

Main Methods:

• Retrospective study of 40 patients (13-88 years) with voice disorders.
• Serum bFGF levels measured before and after intracordal trafermin injection.
• Statistical analysis including Pearson correlation and generalized linear model regression.

Main Results:

• Mean serum bFGF decreased from 6.689 pg/mL pre-injection to 4.658 pg/mL post-injection.
• A moderate positive correlation (r=0.52) was found between trafermin dosage and post-injection bFGF.
• Trafermin dosage was the predominant factor associated with post-injection bFGF levels.

Conclusions:

• Serum bFGF concentrations after intracordal trafermin injection are dose-dependent.
• The observed changes in bFGF are negligible within the physiological range.
• Intracordal trafermin injections appear safe, similar to other administration routes.